cell and gene therapy

Photo
04.12.2023 • News

RoslinCT to Join Manufacturing Network for CRISPR-Based Therapy

UK’s RoslinCT, a cell and gene therapy contract development and manufacturing organization, will be part of the Vertex Pharmaceuticals global network producing the CRISPR-based therapy exa-cel, which will be used for treatment of sickle cell disease and transfusion-dependent beta thalassemia.

Photo
19.07.2022 • News

Vertex Buys ViaCyte for $320 Million

US-based Vertex Pharmaceuticals has agreed to pay $320 million in cash to acquire ViaCyte, a compatriot private cellular therapy company specializing in a treatment for type-1 diabetes (T1D). The transaction is expected to close later this year.

Photo
18.07.2022 • News

Solvias Boosts Testing Services with Cergentis Buy

Solvias, a Swiss CDMO serving the pharmaceutical, biotechnology, material science and cosmetic industries, has acquired Dutch biotech Cergentis for an undisclosed sum. The deal bolsters Solvias’ platform of biologics and cell and gene therapy (CGT) testing solutions.

Photo
20.04.2022 • NewsStrategy

Ramping Up Biomanufacturing Capacity

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.

Photo
25.02.2021 • News

Catalent to Acquire Delphi Genetics

Leading US gene therapy CDMO Catalent is buying all shares of another CDMO in the same field, plasmid DNA (pDNA) specialist’s Delphi Genetics, headquartered at Gosselie, Belgium. Concurrently, the New Jersey-based company is launching pDNA development and manufacturing services at its Rockville, Maryland, facility.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.